Market Cap
$237.8M
SION
Sionna Therapeutics, Inc.
$5.07 ▼ -0.49%
Prev close $5.10Market cap$237.8M
ConsensusSell
12-mo target$21.00 (+313.8%)
▼ Bearish
Analyst conviction 4/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)25 New Institutional Positions13 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on SION right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Hold (35%)
Inst. Holders
50 funds
Inst. Value
$1.2B
Inst. Activity
25 buys / 13 sells
Insider Activity
$0.00 buy / $118.5M sell
Insider Net $
-$118.5M
Social Sentiment
50° Neutral
SEC Reports
14
Press Releases
2
Price chart 30d -30.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 24, 2026 other
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
Sep 17, 2026 Insider
Cloonan Michael disposed of 436,100 shares
President & CEO
Sep 17, 2026 Insider
Fitzpatrick Jennifer was granted 28,133 shares
CLO and Head of Program Mgmt.
Sep 17, 2026 Insider
Aug 10, 2026 SEC Fitzpatrick Jennifer was granted 28,132 shares
CLO and Head of Program Mgmt.
Sionna Therapeutics announced that its Phase 2a PreciSION CF trial of SION-719 failed to meet its key activity endpoint
8-K — Impact 7/10
Sionna Therapeutics reported Q2 2026 financial results with a net loss of $29.9M ($-0.66/share), wider than the $18.1M l
8-K — Impact 4/10
Three insiders at Sionna Therapeutics (SION) sold a total of $8.16M in shares over a 7-day window, representing 0.41% of
CLUSTER — Impact 4/10
Jun 30, 2026 Inst.
ADAGE CAPITAL PARTNERS GP, — DOUBLED
1,600,000 shares ($70.4M)
Analyst ratings buy % -59.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
35% rate it Buy or better · 17 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 15, 2026 | Wedbush | MAINTAIN | Neutral | 57% |
| Aug 11, 2026 | Guggenheim | DOWNGRADE | Neutral | 52% |
| Aug 11, 2026 | Wedbush | DOWNGRADE | Neutral | 57% |
| Aug 10, 2026 | BTIG | DOWNGRADE | Neutral | 53% |
| Aug 7, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| May 26, 2026 | Citizens | REITERATE | Market Outperform | 38% |
| May 20, 2026 | Freedom Broker | DOWNGRADE | Hold | 66% |
| May 18, 2026 | Stifel | MAINTAIN | Buy | 54% |
| May 13, 2026 | BTIG | REITERATE | Buy | 53% |
| May 5, 2026 | Wedbush | INITIATE | Outperform | 57% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 4 | 11 | 0 | 0 | 35% | |
| Aug 1, 2026 | 7 | 7 | 2 | 1 | 0 | 82% | |
| Jul 1, 2026 | 7 | 7 | 2 | 1 | 0 | 82% | |
| Jun 1, 2026 | 7 | 7 | 2 | 1 | 0 | 82% | |
| May 1, 2026 | 6 | 8 | 1 | 1 | 0 | 88% | |
| Apr 1, 2026 | 6 | 8 | 1 | 1 | 0 | 88% | |
| Mar 1, 2026 | 6 | 8 | 1 | 1 | 0 | 88% | |
| Feb 1, 2026 | 6 | 6 | 1 | 1 | 0 | 86% |
Price targets
Where 7 covering analysts think SION trades over the next 12 months.
$21.00 +313.8% upside Strong Buy
Current$5.08 Low$5.00 Median$6.00 High$63.00 7 analysts
$5.00$63.00
Analyst rating None as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
14 SEC filing reports analyzed · 0 bullish, 7 bearish, 0 mixed, 7 neutral · avg impact 5.1/10.Plus 2 press releases.
BEARISH8-K7/10
Sionna Therapeutics announced that its Phase 2a PreciSION CF trial of SION-719 failed to meet its ke
Aug 10, 2026
NEUTRAL8-K4/10
Sionna Therapeutics reported Q2 2026 financial results with a net loss of $29.9M ($-0.66/share), wid
Aug 6, 2026
NEUTRALCLUSTER4/10
Three insiders at Sionna Therapeutics (SION) sold a total of $8.16M in shares over a 7-day window, r
Jul 10, 2026
BEARISHCLUSTER5/10
Three Sionna insiders sold a combined $9.57M in open-market sales over a 7-day window, including a d
Jul 9, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 24, 2026
other
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "C
Sep 18, 2026
short_volume
Short Volume: SION — 58.2% short (0.5M / 0.8M)
Short: 476,584 | Exempt: 38,555 | TRF Vol: 818,622 | Short Ratio: 58.2% | Off-exchange volume (dark pool + OTC)
Sep 14, 2026
other
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 bi
Sep 10, 2026
Clinical Trial
Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta
Phase Phase 2 — COMPLETED
Sep 10, 2026
other
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "C
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.68 | $-0.84–$-0.53 | -47.3% | -0.6% | 3↑ 4↓ | $0.0B | 8 |
| Next Q | $-0.55 | $-0.68–$-0.37 | -19.8% | +11.4% | 5↑ 3↓ | $0.0B | 8 |
| Current FY | $-2.45 | $-2.64–$-1.93 | -30.1% | +4.6% | 4↑ 5↓ | $0.0B | 10 |
| Next FY | $-2.23 | $-3.18–$-1.24 | 8.8% | +11.8% | 4↑ 5↓ | $0.0B | 10 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.677 | — |
| 7d ago | $-0.674 | -0.004 |
| 30d ago | $-0.674 | -0.004 |
| 60d ago | $-0.651 | -0.026 |
| 90d ago | $-0.651 | -0.026 |
Institutional ownership
Which big funds own SION (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.2B total value (27,761,758 shares) as of 2026-Q2. Top holders: RA, VIKING, ADAGE. Net buying activity: 25 institutions added/increased vs 13 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 9,905,045 | $435.7M | 35.7% | — |
| VIKING GLOBAL INVESTORS LP | 3,195,181 | $140.6M | 11.5% | — |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,600,000 | $70.4M | 5.8% | DOUBLED +966.7% |
| BlackRock, Inc. | 1,474,769 | $64.9M | 5.3% | — |
| JPMORGAN CHASE & CO | 1,490,508 | $64.1M | 5.3% | — |
| JENNISON ASSOCIATES LLC | 1,172,133 | $51.6M | 4.2% | ADD +30.1% |
| CITADEL ADVISORS LLC | 1,147,636 | $50.5M | 4.1% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,132,001 | $49.8M | 4.1% | — |
| STATE STREET CORP | 1,021,534 | $44.9M | 3.7% | ADD +35.1% |
| GEODE CAPITAL MANAGEMENT, LLC | 457,145 | $20.1M | 1.6% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | DOUBLED | 150,000 | 1,600,000 | +966.7% | $70.4M |
| STATE STREET CORP | ADD | 756,227 | 1,021,534 | +35.1% | $44.9M |
| GOLDMAN SACHS GROUP INC | ADD | 263,174 | 388,810 | +47.7% | $17.1M |
| DRIEHAUS CAPITAL MANAGEMENT LLC | DOUBLED | 76,633 | 385,447 | +403.0% | $17.0M |
| Aberdeen Group plc | TRIM | 564,175 | 284,138 | -49.6% | $12.5M |
| FMR LLC | DOUBLED | 81,395 | 278,292 | +241.9% | $12.2M |
| MILLENNIUM MANAGEMENT LLC | ADD | 140,641 | 276,733 | +96.8% | $12.2M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | 142,081 | 222,949 | +56.9% | $9.8M |
| Ensign Peak Advisors, Inc | TRIM | 255,636 | 184,532 | -27.8% | $8.1M |
| NORTHERN TRUST CORP | ADD | 116,776 | 154,476 | +32.3% | $6.8M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
14 insiders, 50 transactions. Net -$118.5M — $0.00 bought, $118.5M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | Cloonan Michael | President & CEO | D | 436,100 | — | — |
| Sep 17, 2026 | Fitzpatrick Jennifer | CLO and Head of Program Mgmt. | AWARD | 28,133 | — | — |
| Sep 17, 2026 | Fitzpatrick Jennifer | CLO and Head of Program Mgmt. | AWARD | 28,132 | — | — |
| Sep 17, 2026 | Fitzpatrick Jennifer | CLO and Head of Program Mgmt. | D | 103,140 | — | — |
| Sep 17, 2026 | McKee Charlotte | CMO and Head of R&D | AWARD | 50,000 | — | — |
| Sep 17, 2026 | Ridloff Elena | CFO and CBO | AWARD | 165,440 | — | — |
| Sep 17, 2026 | Ridloff Elena | CFO and CBO | D | 165,440 | — | — |
| Sep 17, 2026 | McKee Charlotte | CMO and Head of R&D | AWARD | 155,700 | — | — |
| Sep 17, 2026 | McKee Charlotte | CMO and Head of R&D | D | 155,700 | — | — |
| Sep 17, 2026 | Ridloff Elena | CFO and CBO | AWARD | 47,269 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for SION.
Shares short
3,966,138
Settlement Sep 15, 2026
Change vs prior
-7.7%
Semi-monthly cycle
Days to cover
3.1
At avg daily volume
Of shares outstanding
≈8.8%
Estimate — not % of float
All SION filing & press-release reports (16)
- 8-K reportAug 10, 2026
- 8-K reportAug 6, 2026
- CLUSTER reportJul 10, 2026
- CLUSTER reportJul 9, 2026
- CLUSTER reportJul 7, 2026
- CLUSTER reportJul 3, 2026
- INST-CLUSTER reportJun 11, 2026
- CLUSTER reportMay 30, 2026
- 144 reportMay 29, 2026
- 8-K reportMay 12, 2026
- PRESS-RELEASE reportMay 12, 2026
- CLUSTER reportMay 11, 2026
- PRESS-RELEASE reportApr 27, 2026
- CLUSTER reportApr 22, 2026
- CLUSTER reportApr 16, 2026
- PRESS-RELEASE reportMar 2, 2026